GILD
Gilead Sciences Inc.
as of 12-16-2025 3:40pm EST
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Frequently Asked Questions
Learn more about our GILD ML prediction model
What parameters are used to train the GILD ML model?
Our stocks GILD ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.
How often is the GILD ML model updated?
We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.
Why might the model accuracy vary?
Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.
How can I contribute data to improve accuracy?
We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.
Are shorter timeframe predictions available?
Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.
Should I use this for financial decisions?
Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.
Share on Social Networks:
Disclaimer
Our GILD ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"GILD Forecast & Prediction for December 17, 2025 Gilead Sciences Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.